Breaking News

Boehringer's AML Drug Gains Orphan Status

April 17, 2014

Volasertib being evaluated in patients with limited treatment options

Boehringer Ingelheim’s volasertib for acute myeloid leukemia (AML) has been granted Orphan Drug Designation by the FDA and European Commission. Volasertib is being evaluated in a Phase III trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for intensive remission induction therapy.
 
Volasertib is an investigational compound that inhibits Plk1 enzymes, which regulates cell division and can result in prolonged cell cycle arrest, ultimately leading to cell death. AML is an aggressive cancer of the bone marrow and blood and has one of the lowest survival rates of all leukemias.
 
In both the U.S. and EU, Orphan Drug Designation is a status given to investigational compounds intended to treat a rare disease or condition that has limited treatment options.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks